Octreotide Dosing in the Medical Management of Chyle Leak Following Otolaryngologic, Thoracic, and Trauma Surgery: A 9-Year Evaluation
- 13 September 2022
- journal article
- research article
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (1) , 93-99
Abstract
Background: Chyle leak is a rare complication following otolaryngologic, thoracic, and trauma surgery wherein the thoracic duct is transected. Case reports and small case series describe octreotide for the medical management of chyle leak, but limited data exist to determine the ideal dose. Objective: To evaluate octreotide dosing in patients with acute chyle leak. Methods: This retrospective, single center, cohort study evaluated adult patients admitted to the otolaryngology, cardiothoracic, and trauma surgery teams over a 9-year period. Patients diagnosed with a chyle leak who received octreotide were eligible for inclusion. Groups were defined as successful medical management or failure requiring definitive surgery. The primary endpoint was daily octreotide dose between groups. Results: Forty-seven patients were included with 29 (61.7%) admitted to the otolaryngology service and 44 (93.6%) with surgical complication as the chyle leak cause. Thirty-two (68.1%) patients had successful medical management while 15 (31.9%) patients failed and required surgical intervention. There was no difference in median daily octreotide dose (250 [IQR, 170-288] µg vs 253 [IQR, 200-282] µg, P = .9). Octreotide weight-based dose, treatment duration, and route of administration were similar between groups. Daily drain output and complete bowel rest were significantly higher in the failure group. Daily drain output was identified as an independent risk factor for failure. Conclusion: Octreotide dose was similar in patients with and without successful medical management of chyle leak. Future studies are needed to determine optimal octreotide dosing and elucidate the relationship between octreotide, drain output, and surgical intervention need.Keywords
This publication has 16 references indexed in Scilit:
- Use of Octreotide for the Management of Chyle Fistula Following Neck DissectionJAMA Otolaryngology–Head & Neck Surgery, 2015
- Spontaneous Hemothorax Caused by Pulmonary Micro-Venous HemangiomaThe Annals of Thoracic Surgery, 2015
- High-Dose Intravenous Octreotide Is Safe and May Be Superior to Surgery in Managing Severe Postesophagectomy Chylothorax in High-Risk PatientsThe Annals of Thoracic Surgery, 2015
- Etiology of Chylothorax in 203 PatientsMayo Clinic Proceedings, 2005
- Somatostatin for Postoperative Chylothorax after Surgery for Children with Congenital Heart DiseaseJournal of Korean Medical Science, 2005
- Preventing of chylothorax after oesophagectomy by routine pre-operative administration of oral creamEuropean Journal of Cardio-Thoracic Surgery, 2001
- Octreotide for protein-losing enteropathy with intestinal lymphangiectasiaThe Lancet, 1995
- Management of Chylothorax after Blunt Chest Trauma1988
- Effect of Somatostatin on the Flow Rate and Triglyceride Levels of Thoracic Duct Lymph In Normal and Vagotomized DogsDiabetes, 1981
- ChylothoraxThe Annals of Thoracic Surgery, 1971